

EDSS: Percentage Change from Part 1 baseline to each scheduled efficacy visit in Part 2  
 Subgroup Analysis: Confirmed Progression of disability  
 ITT population

Confirmed Progressors

|   | Placebo to<br>Natalizumab 300 mg | Natalizumab<br>300 mg | p-value (a) |
|---|----------------------------------|-----------------------|-------------|
| Percentage change from Baseline to Week 156 |                                  |                       |             |
| n   | 162                              | 141                   |             |
| Mean  | 7.23                             | 7.30                  | 0.9121      |
| SD  | 13.513                           | 15.728                |             |

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS ( $\leq 5.5$  or  $\geq 6$ ).

EDSS: Percentage Change from Part 1 baseline to each scheduled efficacy visit in Part 2  
 Subgroup Analysis: Confirmed Progression of disability  
 ITT population  
 Page 12 of 12  
 Non Progressors

|   | Placebo to<br>Natalizumab 300 mg | Natalizumab<br>300 mg | p-value (a) |
|---|----------------------------------|-----------------------|-------------|
| Percentage change from Baseline to Week 156 |                                  |                       |             |
| n   | 98                               | 134                   |             |
| Mean  | -6.47                            | -4.29                 | 0.2594      |
| SD  | 13.951                           | 15.266                |             |

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS ( $\leq 5.5$  or  $\geq 6$ ).